NASDAQ:REPL Replimune Group (REPL) Stock Price, News & Analysis $10.37 -0.35 (-3.26%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$10.25▼$11.0150-Day Range$8.09▼$11.0652-Week Range$4.92▼$20.18Volume432,165 shsAverage Volume1.14 million shsMarket Capitalization$636.87 millionP/E RatioN/ADividend YieldN/APrice Target$16.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Replimune Group alerts: Email Address Replimune Group MarketRank™ Stock AnalysisAnalyst RatingBuy3.17 Rating ScoreUpside/Downside56.2% Upside$16.20 Price TargetShort InterestBearish9.87% of Shares Sold ShortDividend StrengthN/ASustainability-1.28Upright™ Environmental ScoreNews Sentiment0.73Based on 3 Articles This WeekInsider TradingSelling Shares$210,096 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.13) to ($2.73) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.38 out of 5 starsMedical Sector107th out of 910 stocksBiological Products, Except Diagnostic Industry13th out of 155 stocks 3.6 Analyst's Opinion Consensus RatingReplimune Group has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageReplimune Group has only been the subject of 3 research reports in the past 90 days.Read more about Replimune Group's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.87% of the outstanding shares of Replimune Group have been sold short.Short Interest Ratio / Days to CoverReplimune Group has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Replimune Group has recently increased by 2.71%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldReplimune Group does not currently pay a dividend.Dividend GrowthReplimune Group does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreReplimune Group has received a 69.41% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" product. See details.Environmental SustainabilityThe Environmental Impact score for Replimune Group is -1.28. Previous Next 3.2 News and Social Media Coverage News SentimentReplimune Group has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Replimune Group this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for REPL on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows4 people have added Replimune Group to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Replimune Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $210,096.00 in company stock.Percentage Held by Insiders20.60% of the stock of Replimune Group is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.53% of the stock of Replimune Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Replimune Group's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Replimune Group are expected to grow in the coming year, from ($3.13) to ($2.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Replimune Group is -3.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Replimune Group is -3.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReplimune Group has a P/B Ratio of 1.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Replimune Group's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Deal MakerThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.Learn more about this much-needed advancement and investment opportunity here. About Replimune Group Stock (NASDAQ:REPL)Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Read More REPL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart REPL Stock News HeadlinesAugust 21, 2024 | insidertrades.comEmily Luisa Hill Sells 8,938 Shares of Replimune Group, Inc. (NASDAQ:REPL) StockSeptember 5 at 6:29 PM | markets.businessinsider.comStockholders Vote to Elect Madhavan Balachandran to Board of DirectorsSeptember 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. September 3, 2024 | seekingalpha.comReplimune: Strong Data In A Highly Differentiated SpaceAugust 31, 2024 | americanbankingnews.comEquities Analysts Offer Predictions for Replimune Group, Inc.'s Q2 2025 Earnings (NASDAQ:REPL)August 29, 2024 | americanbankingnews.comReplimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of "Buy" from AnalystsAugust 29, 2024 | americanbankingnews.comReplimune Group, Inc. (NASDAQ:REPL) Expected to Earn Q3 2025 Earnings of ($0.88) Per ShareAugust 29, 2024 | americanbankingnews.comReplimune Group (NASDAQ:REPL) Stock Rating Upgraded by Roth CapitalSeptember 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. August 29, 2024 | americanbankingnews.comReplimune Group (NASDAQ:REPL) Coverage Initiated by Analysts at Roth MkmAugust 14, 2024 | finanznachrichten.deReplimune Group Inc: Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced MelanomaAugust 13, 2024 | globenewswire.comReplimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced MelanomaAugust 8, 2024 | investorplace.comREPL Stock Earnings: Replimune Group Beats EPS for Q1 2025August 8, 2024 | finance.yahoo.comReplimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate UpdateJuly 30, 2024 | globenewswire.comReplimune to Present at Two Upcoming Investor ConferencesJune 7, 2024 | globenewswire.comReplimune to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceJune 6, 2024 | globenewswire.comReplimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed MelanomaJune 3, 2024 | globenewswire.comReplimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingSee More Headlines Receive REPL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:REPL CUSIPN/A CIK1737953 Webwww.replimune.com Phone(781) 222-9600FaxN/AEmployees210Year Founded2015Price Target and Rating Average Stock Price Target$16.20 High Stock Price Target$17.00 Low Stock Price Target$14.00 Potential Upside/Downside+56.2%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-215,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-52.15% Return on Assets-41.55% Debt Debt-to-Equity Ratio0.16 Current Ratio13.46 Quick Ratio13.46 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.10 per share Price / Book1.70Miscellaneous Outstanding Shares61,415,000Free Float48,764,000Market Cap$636.87 million OptionableOptionable Beta1.22 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Philip Astley-Sparke F.S.A. (Age 53)CEO & Director Comp: $1.07MDr. Sushil Patel Ph.D. (Age 53)Chief Strategy Officer Comp: $665.05kDr. Robert Coffin Ph.D. (Age 59)Founder, President, Chief Research & Development Officer and Director Comp: $785.89kMs. Emily Luisa Hill (Age 44)Chief Financial Officer Dr. Colin A. Love Ph.D. (Age 66)Chief Operating Officer Comp: $419.37kMr. Andrew Schwendenman (Age 48)Chief Accounting Officer & Treasurer Dr. Pamela Esposito Ph.D. (Age 50)Chief Business Officer Comp: $464.63kMs. Tanya N. Lewis M.S. (Age 53)Chief Development Operations Officer Comp: $4.7kMr. Christopher Sarchi (Age 56)Chief Commercial Officer Dr. Konstantinos Xynos M.B.A. (Age 58)M.D., Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsVir BiotechnologyNASDAQ:VIRAlloVirNASDAQ:ALVRbluebird bioNASDAQ:BLUEAtara BiotherapeuticsNASDAQ:ATRABeam TherapeuticsNASDAQ:BEAMView All CompetitorsInsiders & InstitutionsEmily Luisa HillSold 8,938 sharesTotal: $90,988.84 ($10.18/share)Algert Global LLCBought 4,340 shares on 8/16/2024Ownership: 0.123%Millennium Management LLCBought 2,656,173 shares on 8/15/2024Ownership: 4.564%Point72 Asia Singapore Pte. Ltd.Bought 49,261 shares on 8/15/2024Ownership: 0.072%Deerfield Management Company L.P. Series CSold 773,684 shares on 8/15/2024Ownership: 0.043%View All Insider TransactionsView All Institutional Transactions REPL Stock Analysis - Frequently Asked Questions How have REPL shares performed this year? Replimune Group's stock was trading at $8.43 at the start of the year. Since then, REPL stock has increased by 23.0% and is now trading at $10.37. View the best growth stocks for 2024 here. How were Replimune Group's earnings last quarter? Replimune Group, Inc. (NASDAQ:REPL) issued its earnings results on Thursday, August, 8th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.10. When did Replimune Group IPO? Replimune Group (REPL) raised $100 million in an IPO on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO. Who are Replimune Group's major shareholders? Top institutional shareholders of Replimune Group include Millennium Management LLC (4.56%), Dimensional Fund Advisors LP (0.99%), TD Asset Management Inc (0.37%) and Acadian Asset Management LLC (0.27%). Insiders that own company stock include Robert Coffin, Philip Astley-Sparke, Colin Love, Pamela Esposito, Tanya Lewis, Jean M Franchi, Konstantinos Xynos, Christopher Sarchi, Andrew Schwendenman and Fund Iv LP Omega. View institutional ownership trends. How do I buy shares of Replimune Group? Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Replimune Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU) and Pfizer (PFE). This page (NASDAQ:REPL) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free REPL Stock Alerts